The Mayo Clinic trial was supposed to provide crucial validation of the device’s reliability in detecting the FHR and ease of use compared to a standard handheld fetal doppler. (Mayo’s earlier study had concluded that the doppler was not economic due mainly to the cost of nurses directing patients). Disappointingly, the Herabeat was found to be both less reliable and more difficult to use than the standard handheld doppler.
I sold 80% of my holding upon publication of the results in Feb/March. If the company can prove that the poor results are no impediment to sales, I’ll jump back in. I note, however, that there has been no sales progress since the results were published, and the company has avoided addressing the issue.
HMD Price at posting:
6.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)